Back to Search Start Over

Cell-surface receptor for thyroid hormone and tumor cell proliferation.

Authors :
Davis, Paul J.
Davis, Faith B.
Hung-Yun Lin
Bergh, Joel J.
Mousa, Shaker
Hercbergs, Aleck
Fenstermaker, Robert A.
Ciesielski, Michael J.
Source :
Expert Review of Endocrinology & Metabolism; Nov2006, Vol. 1 Issue 6, p753-761, 9p
Publication Year :
2006

Abstract

Integrin αVβ3 is a structural protein of the plasma membrane that transduces signals from extracellular matrix proteins and has recently been shown to contain a novel receptor for thyroid hormone. Thyroid hormone signals are converted by αVβ3 into mitogen-activated protein kinase (MAPK) (ERK1/2) activation and downstream intracellular events in the cell nucleus. The latter include post-translational modification of the nuclear thyroid hormone receptor (TRβ1) and complex cellular or tissue responses, such as hormone-induced angiogenesis via basic fibroblast growth factor release. The integrin receptor for thyroid hormone has been shown to mediate proliferative effects of the hormone on certain tumor cell lines, including murine glioma/glioblastoma cells and human breast cancer (MCF-7) cells. More than one mechanism may account for this hormonal action, but in vitro studies indicate a direct hormonal action on cellular proliferation. Other possible mechanisms involve indirect actions via the release of tumor growth factors and effects on cell migration. In the intact organism, support of tumor growth by thyroid hormone is postulated to include angiogenesis. Crosstalk between the integrin thyroid hormone receptor and the epidermal growth factor receptor on the plasma membrane may be another mechanism by which thyroid hormone may modify tumor cell growth. Tetraiodothyroacetic acid (tetrac) is an iodothyronine analog that has no agonist activity at the integrin receptor, but inhibits binding of L-thyroxine and 3,5,3′-triiodo-L-thyronine to the receptor, preventing MAPK activation and consequent actions downstream of MAPK. In vitro studies and a preliminary in vivo experiment indicate that tetrac blocks the action of thyroid hormone on tumor cell proliferation. Both unmodified tetrac and tetrac reformulated as a nanoparticle that does not gain access to the cell interior are under investigation in animal models as anticancer agents. Also under study is the susceptibility of other human cancer cell lines to induction of proliferation by physiological concentrations of thyroid hormone. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17446651
Volume :
1
Issue :
6
Database :
Complementary Index
Journal :
Expert Review of Endocrinology & Metabolism
Publication Type :
Academic Journal
Accession number :
26765186
Full Text :
https://doi.org/10.1586/17446651.1.6.753